Immunome Inc. (IMNM)
| Market Cap | 2.21B+33.5% |
| Revenue (ttm) | 0 |
| Net Income | -254.32M |
| EPS | -2.52 |
| Shares Out | 118.00M |
| PE Ratio | n/a |
| Forward PE | -7.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,905 |
| Open | 18.88 |
| Previous Close | 19.09 |
| Day's Range | 18.53 - 18.98 |
| 52-Week Range | 13.49 - 30.06 |
| Beta | 2.56 |
| Analysts | Strong Buy |
| Price Target | 35.20(+88.24%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMNM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMNM from public contracts
Source: USAspending.gov
IMNM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IMNM’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score